

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Roland E. Dolle, et al. Confirmation No.: Not Yet Assigned

Application No.: 10/713,746 Group Art Unit: Not Yet Assigned

Filing Date: November 14, 2003 Examiner: Not Yet Assigned

For: AMIDE DERIVATIVES AND METHODS OF THEIR USE

DATE OF DEPOSIT: Opril 19, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office A	ction on the ments of the above-identified application, or			
before the mailing date of a first Office Action after the filing of request for				
continued examina	tion under § 1.114, no additional fee is required.			
In accordance with	§ 1.129(a), this Information Disclosure Statement is being			
filed in connection	with \square the first or \square second After Final Submission,			
therefore:				
Cert	ification in Accordance with § 1.97(e) is attached; or			
The	fee of \$180.00 as set forth in § 1.17(p) is attached.			
In accordance with § 1.97(c), this Information Disclosure Statement is being				
filed after the period set forth in § 1.97(b) above but before the mailing date of				
either a Final Action	on under § 1.113 or a Notice of Allowance under § 1.311, or			
before an action tha	at otherwise closes prosecution in the application, therefore:			
	Certification in Accordance with § 1.97(e) is attached			
	or			
	The fee of $$180.00$ as set forth in § 1.17(p) is attached.			
In accordance with	a § 1.97(d), this Information Disclosure Statement is being			
filed after the mailing date of either a Final Action under § 1.113 or a Notice				
of Allowance unde	er § 1.311 but before, or simultaneously with, the payment			
of the Issue Fee, t	herefore included are: Certification in Accordance with §			
1.97(e); and the sul	omission fee of $$180.00$ as set forth in $$1.17(p)$.			
Copies of each of	the references listed on the attached Form PTO-1449 are			
enclosed herewith.				

\boxtimes	Copie	s of references listed on the attached Form PTO-1449 are enclosed
	herew	rith
\boxtimes	Copie	s of references listed on the attached Form PTO 1449 are not required to
	be su	bmitted pursuant to the June 30, 2003 recent revisions to 37 CFR §
	1.98(a	a)(2)(i).
	EXC	EPT THAT:
	\boxtimes	In view of the voluminous nature of references 4, 6 and 22, and the
		likelihood that these references are available to the Examiner, copies
		are not enclosed herewith.
		In accordance with § 1.98(d), copies of the following references listed
		on the attached Form PTO-1449 are not enclosed herewith because
		they were previously cited by or submitted to the U.S. Patent and
		Trademark Office in patent application(s) for which a claim for priority
		under 35 U.S.C.§ 120 have been made in the instant application:
		Copies of references [list as appropriate] listed on the
		attached Form PTO-1449 were previously cited by or submitted
		to the Patent and Trademark Office in prior Application No.
		, filed .

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

DOCKET NO.: ADOL-0585

-4
PATENT

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Date: April 19, 2004

Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2004 WW





Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Docket No ADOL-05		Application No. 10/713,746	
			Applicant Roland E. Dolle, et al.			
	U.S. Department of Commerce Patent and Trademark Office			e 14, 2003	Group Not Yet Assigned	
			Confirmat Not Yet A			
ОТ	HE	R DOCUMENTS (Includ	ling Author	, Title, Date, 1	Pertinent Pages, Etc.)	
	1			s suppress spontaneous activity of polymodal nociceptors ultraviolet irradiation," <i>Neurosci.</i> , 1994 , <i>58(4)</i> , 793-798		
	2	Antonijevic, I.et al., "Perineurial defect and peripheral opioid analgesia in inflammation," J. Neurosci., January 1995, 15(1), 165-172				
	3	Barber, A., et al., "Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation," <i>Med. Res. Rev.</i> , 1992, 12(5), 525-562				
*	4	Buschmann, H. (Eds.), et al., Analgesics, Whiley-VCH, Verlag GMbH & Co., KgaA, Weinheim, 2002				
	5	Flynn, G.L., "Mechanism of percutaneous absorption from physicochemical evidence," Percutaneous Absorption, Maibach, H.I., et al. (Eds.), <i>Marcel Dekker Inc.</i> , 1985, 17-42				
*	6	······································				
	7	Handwerker, et al., Pain and Inflammation, Proceeding of the VI th World Congress on Pain, Bond, et al. (Eds.), Elsevier Science Publishers BV, 1990, 59-70				
	8	Hargreaves, K.M., et al., "The peripheral analgesic effects of opioids," APS Journal, 1993, 2(1), 51-59				
	9	Hassan, A.H.S., et al., "Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increase their density in the inflamed tissue, <i>Neuroscience</i> , 1993, 55(1), 185-193			neir density in the inflamed tissue,"	
	Iyengar, S., et al., "Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axisin the rat," J. Pharmacol. Exp. Ther., 1986, 238(2), 429-436					
EXAMINER			DATE CON	SIDERED		

^{*} A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.





Form l	Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			o. 885	Application No. 10/713,746	
C				Applicant Roland E. Dolle, et al.		
		nent of Commerce Frademark Office	Filing Dat		Group Not Yet Assigned	
			Confirmat Not Yet A			
O'	THE	R DOCUMENTS (Includ	ding Author	r, Title, Date,	Pertinent Pages, Etc.)	
	11	Jain, K.K., "A guide to 1 5(2), 241-257	Drug Evalua	tion for chroni	c pain," Emerging Drugs, 2000,	
	Leander, J.D., et al., "Diuresis and suppression of vasopressin by kappa opioids: comparison with Mu and Delta opioids and clonidine," J. Pharm. Exp. Ther., 19, 234, 463-469					
	13	Lurz, R.A., et al., "Opioid reepors and eir parmaologial profiles," J. of Recept. Res., 1992 12(3), 267-286				
	14	Mansour, A., et al., "Anatomical distribution of opioid receptors in mammalians," an overview," <i>Opioid I</i> , 1993 , 79-105				
	15	Manzanares, J., et al., "Kappa-opioid-receptor-mediated regulation of α -melanocyte-stimulating hormone secretion and tuberohypophysial dopaminergic neuronal activity," <i>Neuroendocrinology</i> , 1990 , <i>52</i> , 200-205				
	16					
	17					
	18					
	19	Pershing, L.K., et al., "In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum," <i>Antimicrob. Agents Chemother.</i> , January 1994 , <i>38(1)</i> , 90-95				
	20	Przewlocki,, R., et al., "Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception," <i>Neuroscience</i> , 1992, 48(2), Pergamon Press Ltd., 491-500				
EXAMINER	EXAMINER DATE CONSIDERED					





Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Docket No ADOL-058		Application No. 10/713,746		
			Applicant Roland E.	Applicant Roland E. Dolle, et al.			
	U.S. Department of Commerce Patent and Trademark Office			14, 2003	Group Not Yet Assigned		
			Confirmati Not Yet As				
O'	THE	R DOCUMENTS (Inclu	iding Author,	Title, Date,	Pertinent Pages, Etc.)		
	21	Ramabadran, K., et al., nociceptive reactions in			experimental evaluation of 986 , 3(5), 263-270		
*	22	Remington's Pharmace	eutical Science	s, Mack Publ	lishing Co., 1980		
	23	Roy, S.D., et al., "Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil," <i>Pharm. Res.</i> , 1990, 7(8), 842-847					
	24						
	25						
26 Schaible, HG.et al., "Afferent and spinal mechanisms of joint pain," Pain. 5-54					isms of joint pain,"Pain, 1993, 55,		
	27	Simon, E.J., "Opioid receptors and endogenous opioid peptides," <i>Med. Res. Rev.</i> , 1991, 11(4), 357-374					
	28	Stein, C., et al., "Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of MU, Delta, and Kappa receptors," <i>J. Pharmacol. Exp. Ther.</i> , 1989 , <i>248</i> (3), 1269-1275					
	29						
	30						
EXAMINER	EXAMINER				DATE CONSIDERED		

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.





Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Docket No ADOL-05		Application No. 10/713,746		
			Applicant Roland E. Dolle, et al.				
		nent of Commerce Frademark Office	Filing Dat November		Group Not Yet Assigned		
			Confirmat Not Yet A				
O	THE	R DOCUMENTS (Inclue	ding Author	r, Title, Date, 1	Pertinent Pages, Etc.)		
	31			ist and antagonist interactions of opioids on acetic acidhing in mice," J. or Pharmacol. Exp. Ther., 1969, 169(1),			
	32	Tjølsen, A., et al., "The formalin test: an evaluation of the method," <i>Pain</i> , 1992 , <i>51</i> , 5-17					
	33			dization of the rat paw formalin test for the narmacology, 1991, 104, 35-44			
					Reflex increase in blood pressure induced by leg <i>Physiol.</i> , 1994 , <i>475.2</i> , 351-357		
	35	Wood, P.L., "Multiple of sites," <i>Neuropharmacol</i>			r unique Mu, Delta and Kappa		
· · · · · · · · · · · · · · · · · · ·							
				·. · · · · · · · · · · · · · · · · · ·			
EXAMINER				DATE CONSIDERED			

Form PTO-1449 Modified				Docket No. ADOL-0585	Application No. 10/713,746		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Roland E. Dolle, et al.			
U.S. Department of Commerce Patent and Trademark Office				Filing Date November 14, 2003	Group Not Yet Assigned		
				Confirmation No. Not Yet Assigned			
		U. S	S. PATENT	T DOCUMENTS			
Examiner Initial				Name	Class	Subclass	
	36	4,065,573	12/27/77	Lednicer	424	278	
	37	4,098,904	07/04/78	Szmuszkovicz	424	324	
	38 4,145,435 03/20/79		03/20/79	Szmuszkovicz	424	274	
	39 4,212,878 07/15/80		Lednicer, et al.	424	274		
40 4,359,476 11/16/82		Kaplan, et al.	424	274			
			Kaplan	424	274		
			Horwell, et al.	514	429		
	43	4,906,655	03/06/90	Horwell, et al.	514	422	
	44	5,109,135	04/28/92	D'Ambra, et al.	544	73	
	45	5,242,944	09/07/93	Park, et al.	514	466	
	46	5,345,943	09/13/94	Hargreaves, et al.	128	742	
	47	5,369,131	11/29/94	Poli, et al.	514	772.4	
	48	5,434,292	07/18/95	Saita, et al.	560	51	
	49	5,532,266	07/02/96	Gottschlich, et al.	514	428	
	50	5,688,955	11/18/97	Kruse, et al.	546	276.4	
	51	5,804,595	09/08/98	Portoghese, et al. 514		428	
	52 6,117,438 09/12/00			Topolkaraev, et al.	424	404	
EXAMINE				DATE CONSIDERED)		